Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8636-8645

  Hitt, Ricardo ^a   López Pousa, Antonio ^b   Martínez Trufero, Javier ^b   Escrig, Vicente ^b   Carles, Joan ^b   Rizo, Alfredo ^b   Isla, Dolores ^b   Vega, M Eugenia ^b   Martí, Juan L ^b   Lobo, Francisco ^b   Pastor, Pedro ^b   Valentí, Vicente ^b   Belón, Joaquín ^b   Sánchez, Miguel A ^b   Chaib, Carlos ^b   Pallarés, Cinta ^b   Antón, Antonio ^b   Cervantes, Andrés ^b   Paz Ares, Luis ^b   Cortés Funes, Hernan ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; PACLITAXEL; RANITIDINE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RESEARCH; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY REACTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEURALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; TREATMENT OUTCOME; ADJUVANT THERAPY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; FOLLOW UP; HEAD AND NECK TUMOR; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PROSPECTIVE STUDY; REMISSION; SPAIN; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PACLITAXEL; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 32144460191     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.00.1990     Document Type: Article

References (20)

1. Ferlay J, Bray F, Pisani P, et al: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. International Agency for Research on Cancer (IARC) Cancer Base No. 5, Lyon, France, IARC Press, 2001
2. Harari PM: Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J Clin Oncol 15:2050-2055, 1997
3. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data-MACH-NC Collaborative Group: Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
4. Forastiere AA, Shank D, Neuberg D, et al: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group Trial (PA 390). Cancer 82:2270-2274, 1998
5. Smith RE, Thorton D, Allen J: A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative studies. Semin Oncol 22:41-46, 1995 (suppl 6)
6. Gebbia V, Testa A, Cannata G, et al: Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 32:901-902, 1996
7. Hitt R, Paz-Ares L, Brandariz A, et al: Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: Long-term results of a phase II trial. Ann Oncol 13:1665-1673, 2002
8. Bristol DR: Designing clinical trials for two-sided multiple comparisons with a control. Control Clin Trials 10:142-152, 1989
9. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995
10. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 53:457-481, 1958
11. Grover NB: Two-sample Kolmogorov-Smirnov test for truncated data. Comput Programs Biomed 7:247-250, 1977
12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
13. Tarone R, Ware J: On distribution-free tests for equality of survival distributions. Biometrika 64:156-160, 1977
14. Mazoyer B, Mary JY: Kappa as an index of reproducibility: Distribution under the null-hypothesis. Rev Epidemiol Sante Publique 35:474-481, 1987
15. Mick R, Vokes E, Weichselbaum R, et al: Prognostic factors in advanced head and neck cancer patients undergoing multimodality therapy. Otolaryngol Head Neck Surg 105:62-73, 1991
16. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-3008, 2003
17. Denis F, Garaud P, Bardet E, et al: Final results of 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69-76, 2004
18. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999
19. Kies M, Gordon L, Hauck W, et al: Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer. Otolaryngol Head Neck Surg 93:199-205, 1985
20. Rooney M, Kish J, Jacobs J, et al: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5FU infusion and cisplatin. Cancer 55:1123-1128, 1985